Oct 10 (Reuters) - Drug developer Denali Therapeutics ( DNLI )
said on Thursday its partner Sanofi has
discontinued a mid-stage study testing their experimental drug
to treat multiple sclerosis as it failed to meet the main and
secondary goals.